GSK publishes provisional dividend dates for 2027
GSK plc has announced its indicative dividend schedule for the 2027 calendar year.
Stocks · News reference
Analysts Adjust Ratings and Price Targets for GSK
Financial institutions including Jefferies and Barclays have updated their outlooks on GSK, citing concerns over the company's drug development pipeline and recent quarterly performance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ViiV Healthcare Commits $100M Over Three Years Under Its U.S. Positive Action Program To Support Local HIV Organizations
GSK Chief Digital and Technology Officer Appointed to BAE Systems Board
Shobie Ramakrishnan, GSK's Chief Digital and Technology Officer, has been appointed as a non-executive director of BAE Systems plc, effective February 22, 2027.
GSK Enters Strategic Scientific Collaboration with Alamar Biosciences
GSK has partnered with Alamar Biosciences to utilize the NULISA platform for a large-scale study on protein signatures in various disease conditions.
Berenberg Maintains 'Buy' Rating on GSK
Berenberg has reaffirmed its 'Buy' rating on GSK with a price target of 2200 pence, following the company's third-quarter financial results.
Alfasigma Announces GSK Presentations on Linerixibat at AASLD The Liver Meeting 2026
Alfasigma announced that GSK will present five studies on linerixibat for primary biliary cholangitis (PBC) at the upcoming AASLD The Liver Meeting 2026.